OverviewSuggest Edit

GlycoSeLect is a company that specializes in the development and production of Recombinant Prokaryotic Lectins (RPLs). They enable detection, analysis, separation, and purification of intact glycosylated biomolecules.
TypePrivate
Founded2013
HQDublin 9, IE
Websiteglycoselect.com

Latest Updates

Employees (est.) (Apr 2022)10
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

GlycoSeLect Office Locations

GlycoSeLect has an office in Dublin 9
Show all (1)

GlycoSeLect Financials and Metrics

Summary Metrics

Founding Date

2013

GlycoSeLect total Funding

$528.8 k

GlycoSeLect latest funding size

$528.82 k

Time since last funding

5 years ago

GlycoSeLect investors

GlycoSeLect's latest funding round in October 2017 was reported to be $528.8 k. In total, GlycoSeLect has raised $528.8 k
Show all financial metrics

GlycoSeLect Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

GlycoSeLect Online and Social Media Presence

Embed Graph

GlycoSeLect Blogs

Simplifying Glycoanalysis with Recombinant Prokaryotic Lectins

Glycosylation is a post-translational modification (PTM) that can influence protein structure and function. It is therefore a Critical Quality Attribute (CQA) for biotherapeutic manufacturing, where it must be closely monitored to assure product safety and efficacy. Limitations of current glycoanaly…

Streamline Purification of Glycosylated Proteins with Recombinant Prokaryotic Lectins

Glycosylation affects the safety and efficacy of biologic drugs, making it a Critical Quality Attribute (CQA) for biotherapeutic manufacturing. Recombinant prokaryotic lectins (RPLs) provide several advantages for purifying glycosylated biotherapeutics and are applicable to both glycoanalysis and do…

GlycoSeLect signs distribution agreement with MJS BioLynx Inc.

November 2021 GlycoSeLect is delighted to announce that it has signed an exclusive distribution agreement for its innovative RPL glycan specific technology in the Canadian market with MJS BioLynx Inc. MJS BioLynx Inc. is a Canadian life sciences distribution company with over 40 years of distributio…

GlycoSeLect enters strategic agreement with DBA Italia

Dublin-Milan, September 2021 GlycoSeLect is pleased to announce that we have entered into a strategic agreement with DBA Italia, Milan, Italy. Effective from October 1st, 2021, DBA Italia s.r.l. is appointed as GlycoSeLect’s distributor for Italy for our innovative recombinant lectin products, devot…

New webinar on glycoanalytics features GlycoSeLect

Last month, BioPharm International hosted a webinar on Novel High-Throughput Glycoanalytics for Biopharmaceuticals, sponsored by Sartorius, and aimed at those interested in learning more about the detection of glycans in biopharmaceutical samples. During the presentation, Victoria Smith and Lewis Wh…

Targeting key glycoproteins: Glucose oxidase

Using GlycoSeLect RPL products to enable the isolation and identification of key protein glucose oxidase in a variety of applications. By Simarjot Kaur, Scientist at GlycoSeLect. GlycoSeLect specializes in the manufacture and delivery of Recombinant Prokaryotic Lectins (RPLs), highly specific glycan…
Show more

GlycoSeLect Frequently Asked Questions

  • When was GlycoSeLect founded?

    GlycoSeLect was founded in 2013.

  • How many employees does GlycoSeLect have?

    GlycoSeLect has 10 employees.

  • Who are GlycoSeLect competitors?

    Competitors of GlycoSeLect include Aurobindo Pharma, Unither Pharmaceuticals and Patheon.

  • Where are GlycoSeLect offices?

    GlycoSeLect has an office in Dublin 9.

  • How many offices does GlycoSeLect have?

    GlycoSeLect has 1 office.